Gubra A/S

Equities

GUBRA

DK0062266474

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 10:29:01 2024-06-27 EDT			5-day change	1st Jan Change
462 ^DKK	+3.36%		+6.42%	+271.20%

05-07	Gubra A/S Announces Management Changes	CI
04-17	Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss	CI

Gubra A/S Announces Management Changes

May 07, 2024 at 01:30 am

Gubra A/S announced that as of July 1st 2024 its new CSO will be Louise Schjellerup Dalbøge. Louise is currently Research Director at Gubra and has been intensively involved in the development of current R&D pipeline. Louise brings extensive scientific expertise.

At the same time its current CSO and Gubra?s co-founder Niels Vrang will transition to a new role and be employed as Scientific Advisor to Gubra?s Executive Management. Also, the company has initiated the process of identifying a new COO to prepare for the next growth waves of Gubra. Former COO Helle K. Erichsen will be pursuing other opportunities.

Latest news about Gubra A/S

Gubra A/S Announces Management Changes	05-07	CI
Gubra Unveils UCN2 as Novel Anti-Obesity Drug Candidate for Healthy Weight Loss	04-17	CI
Certain Shares of Gubra A/S are subject to a Lock-Up Agreement Ending on 29-MAR-2024.	03-28	CI
Gubra Concludes the Research Agreement with Silence Therapeutics plc	01-26	CI
Gubra and Boehringer Ingelheim Sign 4Th Partnership, Expanding Their Successful Obesity Treatment Discovery Collaboration	12-13	CI
Gubra A/S Announces First Subject Dosed in Phase 1 Clinical Trial of Amylin Agonist for the Treatment of Obesity	11-29	CI
Gubra A/S Announces Board Appointments	11-01	CI
Gubra Raises Earnings Guidance for Full-Year 2023	23-10-26	CI
Denmark's Gubra Opens First US Office Under Expansion Strategy	23-10-24	MT
Gubra A/S Opens Its First US Office in Boston	23-10-24	CI
Gubra Seeks UK Regulatory Approval to Begin Human Trial for Anti-Obesity Drug	23-09-06	MT
Gubra A/S Submits Clinical Trial Application for First-In-Human Amylin Trial	23-09-06	CI
Tranche Update on Gubra A/S's Equity Buyback Plan announced on June 30, 2023.	23-08-25	CI
Gubra Announces Termination of Collaboration with Bayer AG	23-08-23	CI
Gubra A/S Raises Financial Guidance for Full-Year 2023	23-08-15	CI
Gubra A/S commences an Equity Buyback Plan for 1,180,424 shares, under the authorization approved on March 16, 2023.	23-06-30	CI
Gubra A/S acquired Minigut Aps for DKK 5.96 million.	23-06-28	CI
Gubra A/S Announces Updates to Its Pipeline	23-06-09	CI
Gubra A/S and Boehringer Ingelheim Share Phase 1 Results for BI 1820237	23-05-17	CI
Gubra A/S Provides Revenue Guidance for the Year 2023	23-05-11	CI
Danish Biotech Gubra's IPO Overallotment Option Partly Exercised	23-05-02	MT
Gubra A/S(CPSE:GUBRA) added to OMX Nordic All-Share Index	23-04-10	CI
Gubra A/S has completed an IPO in the amount of DKK 500.00005 million.	23-03-30	CI
Gubra A/S has filed an IPO in the amount of DKK 500.00005 million.	23-03-20	CI

Chart Gubra A/S

Duration

Period

More charts

Company Profile

Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Companyâs operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GUBRA A/S	+271.20%	1.04B
VERTEX PHARMACEUTICALS INCORPORATED	+17.18%	122B
REGENERON PHARMACEUTICALS, INC.	+20.85%	115B
ARGENX SE	+20.93%	26.64B
BIONTECH SE	-23.20%	19.91B
GENMAB A/S	-17.08%	16.32B
WUXI APPTEC CO., LTD.	-44.74%	15.52B
BEIGENE, LTD.	-19.31%	15.49B
SAREPTA THERAPEUTICS, INC.	+59.90%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+2.19%	13.67B

Bio Therapeutic Drugs